Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Anteris Technologies Global Corp. Common Stock (AVR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AVR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 287.16M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 232581 | Beta 0.74 | 52 Weeks Range 3.05 - 8.79 | Updated Date 04/1/2025 |
52 Weeks Range 3.05 - 8.79 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2678.44% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) -840.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 279733221 | Price to Sales(TTM) 101.59 |
Enterprise Value 279733221 | Price to Sales(TTM) 101.59 | ||
Enterprise Value to Revenue 103.18 | Enterprise Value to EBITDA - | Shares Outstanding 35939800 | Shares Floating 17135301 |
Shares Outstanding 35939800 | Shares Floating 17135301 | ||
Percent Insiders 7.63 | Percent Institutions 45.17 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anteris Technologies Global Corp. Common Stock
Company Overview
History and Background
Anteris Technologies Ltd. (formerly known as Admedus Ltd.) is an Australian-based medical technology company. Founded in 2000, it focuses on developing and commercializing innovative technologies for structural heart disease. It has evolved from a broader medical products company to a dedicated structural heart solutions provider.
Core Business Areas
- AdmedusRegenerative Tissue: Anteris' core business revolves around its ADAPT tissue engineering technology, which is used to create durable and biocompatible tissue for heart valve replacements. Focus is on bovine pericardial tissue processing.
- DurAVRu2122 Aortic Valve: Their primary product is the DurAVRu2122 aortic valve, a single-piece aortic heart valve designed for rapid valve replacement and long-term durability.
Leadership and Structure
The leadership team consists of Wayne York as Chairman, Chris Thompson as CEO, and other key executives overseeing operations, research and development, and commercialization. The company has a board of directors that provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- DurAVRu2122 Aortic Valve: DurAVRu2122 is a transcatheter heart valve (THV) designed to mimic the natural valve. It aims to address limitations of existing heart valve technologies, and potentially has a significant impact on clinical outcomes. Market share is currently low (under 1% currently as it's in clinical trials, but has the potential for significant uptake if the trials are successful). Competitors include Edwards Lifesciences (EW) and Medtronic (MDT). Revenue from DurAVR is minimal currently due to clinical stage.
- ADAPT Tissue: ADAPT is tissue technology that provides anit-calcification used for various cardiovascular procedures. Revenues and market share is minimal. Competitors include tissue processing companies.
Market Dynamics
Industry Overview
The structural heart market is experiencing significant growth driven by aging populations and advancements in minimally invasive procedures. The transcatheter aortic valve replacement (TAVR) segment is a major driver.
Positioning
Anteris aims to capture market share in the rapidly growing TAVR market with its DurAVRu2122 valve. Its single-piece design and ADAPT tissue technology are intended to provide improved durability and patient outcomes, offering a competitive edge. They are currently the smallest player but are aiming to become a major player
Total Addressable Market (TAM)
The global heart valve market is projected to reach tens of billions of dollars annually. Anteris is positioning itself to capture a significant share by addressing the limitations of current technologies and offering a novel solution.
Upturn SWOT Analysis
Strengths
- Innovative DurAVRu2122 valve design
- ADAPT tissue technology
- Potential for improved durability
- Focus on single-piece valve construction
Weaknesses
- Currently in clinical trials and not yet commercially available
- Small company size
- Limited financial resources compared to larger competitors
- High regulatory hurdles
Opportunities
- Growing TAVR market
- Potential for market share gains
- Positive clinical trial results
- Partnerships with larger medical device companies
Threats
- Competition from established players
- Regulatory delays
- Clinical trial failures
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- EW
- MDT
Competitive Landscape
Anteris is a small player competing against much larger, well-established companies. Its competitive advantage lies in its innovative valve design and potential for improved clinical outcomes.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to pre-revenue status.
Future Projections: Future growth depends entirely on the successful commercialization of the DurAVRu2122 valve and its adoption by surgeons and hospitals. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials, securing regulatory approvals, and establishing manufacturing capabilities.
Summary
Anteris Technologies is a pre-commercial medical device company with an innovative heart valve technology that has the potential to disrupt the TAVR market. Its success hinges on positive clinical trial results and successful commercialization. The company faces significant risks including competition from established players and regulatory hurdles. The company is early stages so it carries significant risk.
Similar Companies
EW
Edwards Lifesciences Corp
EW
Edwards Lifesciences Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Anteris Technologies website
- Company presentations
- Analyst reports
- Clinical trial publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anteris Technologies Global Corp. Common Stock
Exchange NASDAQ | Headquaters Toowong, QLD, Australia | ||
IPO Launch date 2024-12-13 | Vice Chairman & CEO Mr. Wayne Geoffrey Paterson | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 136 | Website https://anteristech.com |
Full time employees 136 | Website https://anteristech.com | ||
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.